Literature DB >> 24203275

Molecular modeling and docking studies of O-succinylbenzoate synthase of M. tuberculosis--a potential target for antituberculosis drug design.

Madhusudana Pulaganti1, Babajan Banaganapalli, Chaitanya Mulakayala, Suresh Kumar Chitta, Anuradha C M.   

Abstract

Menaquinone is a lipid-soluble naphthoquinone that is essential for various pivotal functions of bacteria. Naphthoquinone is synthesized from chorismate of the shikimate pathway in microorganisms. Due to its absence in humans and animals, menaquinone biosynthesis has been an attractive target for development of antibiotics against a number of important microbial pathogens, such as Mycobacterium tuberculosis (Mtb). In shikimate pathway, O-succinylbenzoate synthase (OSBS) plays a major role and is one of the major potential drug targets. For Mtb-OSBS, a systematic study was conducted to get an insight about Mtb-OSBS enzyme and the corresponding inhibitors using in silico methods. The 3-D model of Mtb-OSBS was built using structure coordinates of Thermobifida fusca. O-succinylbenzoate synthase, the model, was further refined. The active site amino acids have been identified by comparing the template sequence with the Mtb-OSBS sequence. We identified that Lys(108), Asn(140), Asp(138), Lys(110), Glu(189), Ser(236), Asp(188), Arg(27), Tyr(52), and Ser(237) are highly conserved, and these may play a vital role as active residues, similar to that in template protein. As per the competitive binding of substrate (2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate (SHCHC)), we screened the SHCHC through AutoDock 4.0. The SHCHC molecule was further modified structurally and optimized through PRODRG server. Docking of the 12 lead molecules for best interactions with Mtb-OSBS has given an insight that all the lead molecules have shown interactions with active site amino acids of Mtb-OSBS. MD simulation analysis report has shown the stable conformation annotations of Mtb-OSBS. These hypothetical studies create another way to develop more potential drugs against the deadly mycobacterium.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24203275     DOI: 10.1007/s12010-013-0569-4

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  5 in total

1.  Mechanism of MenE inhibition by acyl-adenylate analogues and discovery of novel antibacterial agents.

Authors:  Joe S Matarlo; Christopher E Evans; Indrajeet Sharma; Lubens J Lavaud; Stephen C Ngo; Roger Shek; Kanagalaghatta R Rajashankar; Jarrod B French; Derek S Tan; Peter J Tonge
Journal:  Biochemistry       Date:  2015-10-15       Impact factor: 3.162

2.  Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme.

Authors:  Sumita Karan; Vipin K Kashyap; Syed Shafi; Ajay K Saxena
Journal:  J Mol Model       Date:  2017-07-25       Impact factor: 1.810

3.  Stereoselective Synthesis, Docking, and Biological Evaluation of Difluoroindanediol-Based MenE Inhibitors as Antibiotics.

Authors:  Christopher E Evans; Joe S Matarlo; Peter J Tonge; Derek S Tan
Journal:  Org Lett       Date:  2016-12-01       Impact factor: 6.005

4.  Novel long-chain compounds with both immunomodulatory and MenA inhibitory activities against Staphylococcus aureus and its biofilm.

Authors:  Seoung-Ryoung Choi; Joel Frandsen; Prabagaran Narayanasamy
Journal:  Sci Rep       Date:  2017-01-10       Impact factor: 4.379

5.  Structure-Based Design, Synthesis, and Biological Evaluation of Non-Acyl Sulfamate Inhibitors of the Adenylate-Forming Enzyme MenE.

Authors:  Christopher E Evans; Yuanyuan Si; Joe S Matarlo; Yue Yin; Jarrod B French; Peter J Tonge; Derek S Tan
Journal:  Biochemistry       Date:  2019-03-26       Impact factor: 3.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.